2019 ACR/ARP Annual Meeting

November 8-13, 2019. Atlanta, GA.

View by Number View by Title View Sessions

View by Date

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

Abstract Number: 2521

Rituximab Treatment Is Not Associated with Increased Risk of Infection or Mortality in Refractory SLE Patients: Results from the British Isles Lupus Assessment Group Biologics Registry (BILAG-BR)
Abstract Number: 1000

RKIP, as an Upstream Regulator of Intracellular Signaling, Exerts Anti-arthritic Effect in Fibroblast-like Synoviocyte and Collagen-induced Arthritis
Abstract Number: 1036

RNA Sequencing of PBMCs Reveals Estrogen-Mediated Upregulation of Micro-RNA Processing Machinery
Abstract Number: 2045

RNA Sequencing of Plasma and Urine-derived Extracellular Vesicles from Lupus Nephritis Patients Identifies Disease-associated Small RNA Signatures and Putative Therapeutic Targets
Abstract Number: 1595

Role of Aerobic Exercise in Modulating Fatigue in Women with Systemic Lupus Erythematosus
Abstract Number: 371

Role of Alternative Immunosuppressant Therapy in Management of Cardiac Sarcoidosis
Abstract Number: 2238

Role of Clinical Impact, Disease-specific Knowledge and Beliefs About Medication on Therapeutic Adherence in Rheumatoid Arthritis: An Integrative Structural Equation Modeling Approach
Abstract Number: 2154

Role of Insulin Resistance and Inflammation on Resting Energy Expenditure in Patients with Rheumatoid Arthritis
Abstract Number: 1927

Role of Mitochondrial DNA from OA Patients in Cellular Apoptosis, Senescence and Autophagy
Abstract Number: 39

Role of Sialic Acid in the Aggressive Phenotype of RA FLS
Abstract Number: 2420

Role of T Follicular Helper Cells and T Peripheral Helper Cells in the Activation of B Cells in Sjögren Syndrome
Abstract Number: 24

Role of Trained Immunity in the Pathogenesis of Erdheim-Chester Disease
Abstract Number: 10

Roles of Histone Acetyltransferases CBP/p300 and Transcriptional Factor RORα/REV-ERBα Against TNFα-induced CCL2 Expression in RA-FLSs
Abstract Number: 1877

Romosozumab Improves Lumbar Spine Bone Mineral Density and Bone Strength Greater Than Alendronate as Assessed by Quantitative Computed Tomography and Finite Element Analysis in the ARCH Trial
Abstract Number: 2424

RORγt Antagonist Attenuates Experimental Sialadenitis Like Sjögren’s Syndrome via Inhibition of CD25 Expression on CD4+ T Cells

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].